Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price Target

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX); $5.50 Price 
Target 
SAN FRANCISCO, CA -- (Marketwired) -- 06/11/14 --  Vista Partners
announced today that it has updated coverage on Soligenix, Inc.
(OTCBB: SNGX) and maintained its twelve-month price target of $5.50.
Soligenix, Inc. is a New Jersey based clinical stage
biopharmaceutical company committed to developing products to treat
life-threatening side effects of cancer treatments and serious
gastrointestinal diseases.  
Ross Silver, Principal Analyst at Vista Partners, stated, "Soligenix
has signed an exclusive worldwide collaboration deal with Intrexon
Corporation ($2.4B mkt cap) (NYSE: XON) to develop a novel passive
immunotherapy for Melioidosis." Mr. Silver continues, "Soligenix also
has an exclusive commercial collaboration with SciClone
Pharmaceuticals ($270M mkt cap) (NASDAQ: SCLN) in China for SGX942 in
the treatment of oral mucositis, a potentially billion dollar
market." Mr. Silver continues, "The Company boasts a diverse pipeline
with nine prospective drug candidates. The science behind the
Company's prospective therapies has been and continues to be
validated by a number of significant, important and influential
entities such as government organizations and major pharmaceutical
companies. To date the Company has been awarded approximately $40M
mainly through BARDA, NIH and FDA grants/contracts. The Company has
up to approximately $33 million in active government contract and
grant funding still available to support its associated research
programs through 2018." Mr. Silver concludes, "Company Insiders
exercised options to purchase common shares in May 2014 according to
Form 4's filed at sec.gov. Also, in the past two years Company
Insiders have purchased or exercised options to purchase shares and
no Company Insiders have sold shares during the same period." 
To download a FREE copy of the Soligenix, Inc. research report,
please visit http://www.vistapglobal.com and click the "download
research" icon to gain access to the report.  
About Vista Partners:
 Vista Partners LLC, founded in 2005, is a
Registered Investment Advisor in the States of California and Oregon.
The firm's professional staff has backgrounds in finance, corporate
communications and investment banking. Vista focuses on investing
globally across all market sectors. Vista also provides investment
considerations on publicly traded companies through a platform of
stock research reports, newsletters, company specific webpages and
daily commentary. The platform of products is meant to serve as
potential tools for investors to learn about investment
considerations. It is Vista's mission to provide investors with tools
that may enable them to make profitable investment decisions with the
goal to deliver investment considerations that outperform small, mid
and large cap equity indexes.  
Please follow us on Twitter @VistaPResearch & Facebook at
Vista-Partners to receive updates, thoughts and ideas about and our
coverage universe of companies and more. 
Disclaimer & Disclosure:
 For a full list of disclaimers and
disclosures, please visit our website www.vistapglobal.com or click
here.  
Contact:
Vista Partners
877.215.4813
info@vistapglobal.com 
 
 
Press spacebar to pause and continue. Press esc to stop.